Drug discovery

#AstraZeneca #Biotherapeutics #Drug discovery #Immuno-oncology

Biotech collaboration to accelerate prostate cancer research

Alchemab has collaborated with AstraZeneca to work on a proof-of-concept study to build understanding of the fundamental biology of prostate cancer. Under the agreement, Alchemab’s novel drug discovery platform will be used as a diagnostic tool through the identification of disease biomarkers with potential to inform the development of novel… Read More

#News

#Data #Drug development #Drug discovery

China’s fast-track regulatory reforms not attracting non-Chinese companies

China has reformed its regulatory system in recent years to include various fast-track programs similar to the US, EU and Japan to incentivise the development of drugs for unmet medical needs and serious conditions. However, only a few companies based outside of China have been granted priority review status by… Read More

#News

#Antigen #Drug discovery #Immunology / Virology & Vaccines #Monoclonal antibodies

How to get your drug to market faster

The pressure to take your drug to market faster is increasing. To achieve a successful journey to the first clinical trial phase in the fastest time possible, Eppendorf has identified three key elements that it is addressing in an eBook.  Comply with audit requirements and relevant certifications  Drive process efficiencies… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Drug research #MS #Neuroscience #Stem cells

Mini 3-D brain models could speed up search for MS treatments

Tiny 3-D models that mimic vital aspects of the human nervous system have been developed in a step that could accelerate drug research for neurological conditions such as multiple sclerosis (MS). The millimetre-wide models – created using stem cells from human skin samples – will be… Read More

#News

#Bacteria #Drug discovery #Research

‘Last resort’ antibiotic pops bacteria like balloons

Scientists have revealed how an antibiotic of ‘last resort’ kills bacteria. The findings, from Imperial College London and the University of Texas, may also reveal a potential way to make the antibiotic more powerful. The antibiotic colistin has become a last resort treatment for infections caused by superbugs. However, despite… Read More

#News

#Drug discovery #Proteogenomics #Sitting Down With

The importance of proteogenomics in drug discovery

The latest DDW Sponsored Sitting Down With podcast features Anders Mälarstig, Director of Human Genetics, Pfizer. In this podcast he outlines the role of pQTLs in the drug discovery process and the growing importance of proteogenomics Mälarstig  is currently responsible for developing and applying strategies for new drug targets and… Read More

#Podcasts

#Antibodies #Cell therapy #DNA #Drug delivery #Drug development #Drug discovery #Sequencing

Accelerating antibody discovery by making sequence space accessible

The biggest constraint in discovering new antibodies for immunotherapy is constructing the underlying DNA sequence, says Dr. Aaron Sato, CSO of Twist Bioscience. Inside the human body, the immune system generates antibodies that can target just about any foreign molecule. It does so through DNA recombination and somatic hypermutation –… Read More

#Editor's Choice #Exclusive Content #News

#Corning Life Sciences #Drug delivery #Drug development #Drug discovery #Gene therapy #Genetics #Genetics / genomes #Life sciences #Research

Process Development in Gene Therapy: Four Things to Know

By John Yoshi Shyu, Ph.D. Corning Life Sciences. Gene therapy – the addition, deletion, or modification of genes in living organisms – has been around, at least in concept, since the 1980s. Gene modification or editing incorporates two main strategies: insertion of novel genetic constructs into existing genes, and gene… Read More

#Exclusive Content #News

#Drug discovery #Podcast #Proteogenomics

The importance of proteogenomics in drug discovery: podcast

The latest DDW Sitting Down With podcast features Anders Mälarstig, Director of Human Genetics, Pfizer. In this podcast he outlines the role of pQTLs in the drug discovery process and the growing importance of proteogenomics Mälarstig  is currently responsible for developing and applying strategies for new drug targets and precision… Read More

#Editor's Choice #News

#Covid-19 #Data #Drug delivery #Drug development #Drug discovery #Research

Interim data suggests drug may prevent cytokine storm

Clinical-stage drug development company Noxopharm has announced that in a cohort of 18 patients with moderately severe cases of Covid-19, interim data from its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with the worsening of the virus. “Until enough people are vaccinated to achieve… Read More

#News

#Clinical trial #Drug design #Drug development #Drug discovery #Research

Call to rethink “primitive” clinical trial approaches

Virtual clinical development specialist, Phesi, is calling for clinical trials to be designed using industry modal values (data values that appear most often in historical trials data) to reduce protocol amendments. Phesi analysed 330,000 clinical trials from the past 15 years and found the majority require substantial protocol amendments and… Read More

#News

#Diabetes #Drug development #Drug discovery #Type 2 diabetes

Muscle gene linked to Type 2 diabetes

Research published in Nature Communications by a team from Lund University in Sweden has discovered that in Type 2 diabetes, a specific gene influences muscle stem cells’ ability to create new mature muscle cells. “In people with Type 2 diabetes, the VPS39 gene is significantly less active in the muscle… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug innovation #Immunology / Virology & Vaccines #Pharma #Pharmaceuticals #Vaccines

Integration at its best: Dalton Pharma outlines its CDMO expertise

Dalton Pharma Services, a contract development and manufacturing organisation (CDMO) offers expertise in drug discovery, formulation and process development, custom synthesis, and GMP manufacturing services. Lu Rahman spoke to CEO, Peter Pekos about the company’s ongoing expertise. LR: The company has experience supplying the needs of the orphan drug field… Read More

#Exclusive Content #News #Opinion

#AI #AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Drug delivery #Drug development #Drug discovery

Putting the power into drug design: the important role of AI

Valence’s co-founder and CEO, Daniel Cohen, spoke to Lu Rahman about the company’s plan to empower drug discovery scientists with AI-enabled drug design LR:  Outline of the company and its main initiatives DC: Valence is an interdisciplinary team of scientists and engineers out of Mila, the world’s largest deep learning… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Clinical trial #Drug development #Drug discovery

MHRA authorises treatment to reduce the risk of cardiovascular events

Amarin Corporation has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Great Britain Marketing Authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established… Read More

#News